ELMCRx Solutions and ETS Partnership
ELMCRx Solutions is forging new paths within the healthcare landscape through its strategic alliance with Emerging Therapy Solutions (ETS). This collaboration is tailored to address the innovative and costly challenges posed by cell and gene therapies (CGT). ELMCRx stands out as a pharmacy benefit manager (PBM) dedicated to providing tailored prescription and clinical management services to its clients, ensuring they stay ahead in a rapidly evolving industry.
Understanding Cell and Gene Therapies
Cell and gene therapies have begun to revolutionize medical treatment, offering potential cures for various complex and rare health conditions. However, with these revolutionary treatments comes a significant financial burden. As the pharmaceutical landscape shifts and more of these therapies gain regulatory approval, healthcare providers and employers grapple with managing unpredictable costs.
Enhanced Support Through Risk Management
The partnership between ELMCRx and ETS is timely, offering clients access to advanced risk management strategies for high-cost specialty treatments. ETS specializes in helping businesses manage the financial risks associated with CGT, which can run into the hundreds of thousands or even millions of dollars. This dynamic partnership provides tools designed to mitigate exposure and craft customized solutions that align with individual client needs.
Strategic Planning with ETS Forecasting Services
One of the standout features of this partnership is ETS's forecasting services, which utilize advanced algorithms to analyze client population health. By incorporating insights from the latest clinical trials, expert evaluations, and claims history, ETS empowers businesses to anticipate potential costs and strategize accordingly. This proactive approach means that clients can discover their current exposure levels and find optimal strategies to manage costs and outcomes.
Negotiated Pricing and Access to Specialized Treatments
In a healthcare environment focused on elevating patient outcomes, the role of negotiated pricing becomes essential. By collaborating with ELMCRx, ETS provides clients with insights that enhance their access to treatments at identified 'Programs of Experience.' This enables clients to secure better pricing and thus maintain financial stability while ensuring their members receive the best possible care.
Testimonials from Leadership
AMY Gasbarro, the President of ELMCRx, emphasizes the importance of this partnership, stating, "Cell and gene therapies are at the forefront of many of our clients’ minds, and for good reason. Our partnership with ETS can help businesses be better prepared to face the current and future risks of CGTs." This sentiment echoes the collective mission of ELMCRx and ETS to help businesses navigate the complexities of therapeutic offerings.
Mary Ann Carlisle, CRO and COO of ELMCRx, adds, "There is an element of uncertainty associated with these therapies, but the ELMCRx - ETS partnership allows us to respond to these challenges with opportunities for employers to manage costs while providing members with access to optimal health outcomes." This partnership illustrates a commitment not only to service but also to the well-being of clients and their members.
About ELMCRx Solutions
Founded by experienced industry leaders Richard Fleder and Mary Ann Carlisle, ELMCRx Solutions is focused on innovation in pharmacy benefit management. Their technology-driven services span clinical management and prescription drug administration, prioritizing client needs for cost-effective healthcare solutions. ELMCRx’s diverse suite of specialized services underscores their commitment to meeting the evolving demands of the healthcare landscape.
About Emerging Therapy Solutions
Emerging Therapy Solutions is dedicated to supporting healthcare providers and employers in managing the intricate risks presented by high-cost therapies. With a broad range of services optimized for various therapeutic areas, ETS is a pioneer in solutions for solid organ transplants, bone marrow transplants, and CGT. Their comprehensive support framework emphasizes risk management and cost containment, making them an invaluable partner in today's healthcare environment.
Frequently Asked Questions
What is the purpose of the ELMCRx and ETS partnership?
The partnership aims to provide enhanced risk management and cost savings for cell and gene therapies, helping clients navigate the financial challenges of these treatments.
How does ETS assist clients in managing therapy costs?
ETS employs advanced forecasting services that analyze population health and therapeutic options, enabling clients to anticipate costs and make informed decisions.
Why are cell and gene therapies considered high-cost?
These therapies often involve advanced technologies and extensive development processes, leading to significant costs that can range from hundreds of thousands to millions.
What benefits does ELMCRx provide as a pharmacy benefit manager?
ELMCRx delivers tailored prescription management services, clinical oversight, and cost-containment strategies to ensure that clients optimize their healthcare expenses.
How do clients get access to negotiated pricing for therapies?
Through the partnership with ETS, clients can leverage insights and relationships that help secure better pricing for specialized therapy options at selected treatment facilities.
